Aristotle Capital Boston LLC Sells 9,134 Shares of Charles River Laboratories International, Inc. $CRL

Aristotle Capital Boston LLC lessened its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 9.6% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 86,214 shares of the medical research company’s stock after selling 9,134 shares during the period. Aristotle Capital Boston LLC owned 0.18% of Charles River Laboratories International worth $17,198,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Tema Etfs LLC bought a new stake in Charles River Laboratories International during the fourth quarter valued at about $26,000. Rothschild Investment LLC grew its holdings in Charles River Laboratories International by 82.4% during the third quarter. Rothschild Investment LLC now owns 186 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 84 shares during the period. Los Angeles Capital Management LLC bought a new stake in Charles River Laboratories International during the fourth quarter valued at about $42,000. Sfam LLC bought a new stake in Charles River Laboratories International during the fourth quarter valued at about $43,000. Finally, Activest Wealth Management grew its holdings in Charles River Laboratories International by 10,900.0% during the fourth quarter. Activest Wealth Management now owns 220 shares of the medical research company’s stock valued at $44,000 after purchasing an additional 218 shares during the period. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Price Performance

NYSE:CRL opened at $182.97 on Thursday. The company has a current ratio of 1.36, a quick ratio of 1.03 and a debt-to-equity ratio of 0.90. The company has a market capitalization of $8.81 billion, a P/E ratio of -48.66, a P/E/G ratio of 2.11 and a beta of 1.46. Charles River Laboratories International, Inc. has a 12 month low of $143.06 and a 12 month high of $228.88. The business’s 50-day moving average is $174.31 and its 200 day moving average is $182.64.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Thursday, May 7th. The medical research company reported $2.06 EPS for the quarter, topping analysts’ consensus estimates of $1.96 by $0.10. The company had revenue of $995.83 million for the quarter, compared to the consensus estimate of $977.46 million. Charles River Laboratories International had a positive return on equity of 15.36% and a negative net margin of 4.59%.The firm’s revenue for the quarter was up 1.2% on a year-over-year basis. During the same period in the previous year, the business earned $2.34 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. On average, equities research analysts forecast that Charles River Laboratories International, Inc. will post 11.04 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have issued reports on CRL shares. Barclays boosted their price target on Charles River Laboratories International from $210.00 to $220.00 and gave the company an “overweight” rating in a report on Friday, May 8th. Weiss Ratings lowered Charles River Laboratories International from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday. JPMorgan Chase & Co. dropped their price objective on Charles River Laboratories International from $165.00 to $160.00 and set a “neutral” rating for the company in a research note on Monday, April 13th. UBS Group upped their price objective on Charles River Laboratories International from $170.00 to $175.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 25th. Finally, CLSA raised Charles River Laboratories International from a “hold” rating to an “outperform” rating and upped their price objective for the stock from $167.00 to $219.00 in a research note on Friday, May 29th. Twelve investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $211.00.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.